Please login to the form below

Not currently logged in
Email:
Password:

Novartis launches $20m COVID-19 response fund

Financial grants will be issued to most impacted communities

Novartis

Novartis has announced the launch of a $20m response fund to support communities around the world which have been most impacted by the COVID-19 pandemic.

The Novartis COVID-19 response fund is set to provide $20m in grants to support public health initiatives to help communities manage the challenges posed by the pandemic.

As outbreaks across the world are unfolding at a rapid pace, Novartis has established a fast-track review process that will allow for quick approval and disbursement of grants worth up to $1m.

The Swiss pharma has outlined a rough guideline for potential initiatives that would qualify for a financial grant – although it is not limited to specific areas.

That includes initiatives focused on strengthening local and national healthcare infrastructure, establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of crucial public health information.

It will also look to provide grants for initiatives focused on creating new or enhancing new community health programmes specific to the pandemic response.

In addition to the response fund, Novartis has also entered into collaborative research efforts including the COVID-19 therapeutics accelerator, which was recently launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard.

It has also collaborated on a partnership organised by the Innovative Medicines Initiative, which has a direct focus on COVID-19 therapeutics.

Novartis will also donate several compounds in its libraries that are considered suitable for in-vitro antiviral testing, and is evaluating its existing products to see if they could be effective against the novel coronavirus disease.

This response fund is just the latest in a string of efforts made by pharma companies to help mitigate a pandemic which has quickly swept across the globe.

Biogen has also committed $10m to support global response efforts to the COVID-19 outbreak, and a host of companies, including Gilead, Moderna, Pfizer and more are developing vaccines and therapeutics targeting the virus.

Article by
Lucy Parsons

18th March 2020

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics